FIELD: medicine.
SUBSTANCE: invention relates to oncology and can be used to suppress allodynia induced by bone cancer. The use of the invention relates to a botulinum neurotoxin for suppressing allodynia caused by bone cancer in a patient suffering from bone cancer, where the botulinum neurotoxin is administered at a dose of 10-40 U/kg of the patient.
EFFECT: enhanced suppression of allodynia.
10 cl, 4 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| PEG-YLATED MUTANT TOXIN CLOSTRIDIUM BOTULINUM | 2007 |
|
RU2426739C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| BIOPREPARATIONS COMPOSITIONS FOR INTRAVESICAL INSTILLATION | 2015 |
|
RU2720991C2 |
| LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
